These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
30. Iloprost treatment in pediatric patients with complicated Raynaud's phenomenon. Cekic S; Kilic SS Lupus; 2016 Apr; 25(5):558-60. PubMed ID: 26692039 [No Abstract] [Full Text] [Related]
31. Oral sildenafil for the treatment of Raynaud's phenomenon and digital ulcers secondary to systemic sclerosis. Gore J; Silver R Ann Rheum Dis; 2005 Sep; 64(9):1387. PubMed ID: 16100356 [No Abstract] [Full Text] [Related]
32. Warfarin-associated multiple digital necrosis complicating heparin-induced thrombocytopenia and Raynaud's phenomenon after aortic valve replacement for adenocarcinoma-associated thrombotic endocarditis. Warkentin TE; Whitlock RP; Teoh KH Am J Hematol; 2004 Jan; 75(1):56-62. PubMed ID: 14695634 [TBL] [Abstract][Full Text] [Related]
33. Vasospastic disorders. Etiology, recognition, and treatment. Miller LM; Morgan RF Hand Clin; 1993 Feb; 9(1):171-87. PubMed ID: 8444973 [TBL] [Abstract][Full Text] [Related]
35. [Raynaud's phenomenon: diagnostic and therapeutic aspects]. Soro P; Occhioni G; Spissu M; Trignano M; Dettori G; Bacciu PP; Biglioli P Chir Ital; 1981 Jun; 33(3):647-60. PubMed ID: 7307205 [TBL] [Abstract][Full Text] [Related]
36. Iloprost treatment for refractory Raynaud's phenomenon in two infants. Shouval DS; Mukamel M; Zulian F; Amir J; Harel L Clin Exp Rheumatol; 2008; 26(3 Suppl 49):S105-7. PubMed ID: 18799065 [TBL] [Abstract][Full Text] [Related]
37. Recount of prostaglandin E1 therapy in a patient with Raynaud's phenomenon. DiGiovanni RL; Littlefield JM; Good RG J Am Osteopath Assoc; 1995 Oct; 95(10):572. PubMed ID: 8557544 [No Abstract] [Full Text] [Related]
38. [53-year-old patient with Raynaud's syndrome. polyneuropathia and fingertip necrosis]. Märker-Hermann E Dtsch Med Wochenschr; 2014 May; 139(17):883-4. PubMed ID: 24760690 [No Abstract] [Full Text] [Related]
39. The 'distal-dorsal difference': a thermographic parameter by which to differentiate between primary and secondary Raynaud's phenomenon. Anderson ME; Moore TL; Lunt M; Herrick AL Rheumatology (Oxford); 2007 Mar; 46(3):533-8. PubMed ID: 17018538 [TBL] [Abstract][Full Text] [Related]
40. Sildenafil in the treatment of Raynaud's phenomenon resistant to vasodilatory therapy. Fries R; Shariat K; von Wilmowsky H; Böhm M Circulation; 2005 Nov; 112(19):2980-5. PubMed ID: 16275885 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]